WCCT Global Enrolls Over 150 Patients in Large Phase I Clinical Trial
COSTA MESA, Calif., Dec. 22, 2014 /PRNewswire-iReach/–WCCT Global is known as a CRO that meets or exceeds its recruitment commitments in the conduct of clinical trials in early and late phase research. Again, WCCTG is pleased to report today that they were the largest contributor of patients by over twice as much as the next highest contributor in a competitive phase I clinical trial. The study required a total of 350 patients from 8 sites. WCCT Global was able to enroll, retain and complete 155 patients and the next closest competitor enrolled 74. This is a significant achievement that once again demonstrated the effectiveness of WCCT Global’s patient recruitment division called “In-Site” and its ability to recruit large numbers of quality patients for clinical research.
The patient recruitment division has multiple recruitment strategies; all are focused on notifying patients about the trial and keeping the volunteers engaged throughout the entire screening and in-life study process. Furthermore, the patient recruitment division makes use of cutting-edge technologies and data-driven platforms in order to efficiently recruit patients before or within deadlines. By targeting healthy volunteers and patient populations anywhere in the globe, the IN-SITE team was easily able to for this phase I clinical trial, randomizing more than double the amount of patients from any other site participating in the study. The recruitment success reported today is another validation of the WCCT Global’s In-Site™ recruitment tool.
WCCT Global’s phase I clinical trial facility unit is located in Cypress, California and has over 150 beds for overnight stays. The CPU’s location is ideal for phase I trials because it is easily accessible and in a densely populated part of Orange County, California. Ed Kim, WCCT Global’s Executive Director, Early Clinical Development stated, ” Our phase I unit is designed to run the most efficient phase I clinical trial possible and with that comes the ability to screen an extremely large number of patients needed to enroll a trial on time and ahead of the competition. At WCCT, we pride ourselves in being a leader in phase I development.”